Diabetic foot ulcers affect millions of people around the world. These open sores on the feet come from diabetes and often lead to serious infections. Bacteria that resist standard antibiotics make treatment hard. Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) shared news about its lead drug, Nu-3. Lab tests showed this topical gel keeps working against tough bacteria over time.
Diabetes harms nerves and blood flow in the feet. Small cuts turn into ulcers that do not heal well. About 15% of diabetics get these ulcers at some point. Infections follow, and in bad cases, amputation becomes necessary. The global market for treating these ulcers sits at around $10 billion this year. Experts expect it to grow to $17 billion by 2035 as diabetes cases rise. In the U.S., costs run high because hospital stays and surgeries add up fast. (Precedence Research)
Bacteria like E. coli and MRSA often invade these wounds. Standard antibiotics lose power as bugs build resistance. This crisis, called antimicrobial resistance or AMR, kills over a million people yearly. Diabetic ulcers suffer from multi-drug resistant strains that laugh off common drugs. Patients face longer healing times and higher risks. Biotech firms now hunt for new weapons that bacteria cannot dodge easily.
Lakewood-Amedex Biotherapeutics Inc. focuses on a class of drugs called Bisphosphocins. These antimicrobials attack bacteria in a fresh way. They target the cell membrane without easy escape routes for the bugs. The company went public via direct listing on Nasdaq in late April 2026. Shares jumped on day one, showing investor interest in micro-cap biotech plays. Based in Sarasota, Florida, the firm has run early human trials for Nu-3. Those tests found the gel safe with hints of faster wound healing.
Nu-3 comes as a topical gel for mildly infected diabetic foot ulcers. Past Phase 2a trials showed it clears bacteria quickly at low doses. No major safety issues popped up. The company plans bigger Phase 2b studies soon to nail the best dose. This builds toward Phase 3 trials needed for approval. Peer-reviewed papers back the drug’s speed and broad action against gram-positive and gram-negative bacteria.Â
Today’s announcement covered 21-day lab tests. Researchers grew E. coli and MRSA in dishes with Nu-3. They checked the minimum inhibitory concentration, or MIC, which measures drug strength. For Nu-3, MIC stayed almost the same against both bugs. E. coli saw a tiny rise, while MRSA showed no change. Compare that to ciprofloxacin, a common antibiotic. Its MIC jumped over 2,000 times for E. coli and 600 times for MRSA. Nu-3 even worked on cipro-resistant strains with no cross-resistance.
CEO Kelvin Cooper called this a big win. He noted Bisphosphocins offer broad coverage with low resistance risk. This fits the growing AMR threat. The data backs the drug’s unique action on bacterial membranes. It disrupts them fast without sparking mutations like older drugs do. Such results cut risks in biotech investing, especially for micro-caps chasing niche markets like infected ulcers.
Infected diabetic foot ulcers drain healthcare systems. In North America alone, treatment costs hit $4 billion yearly. New options like Nu-3 could shorten hospital stays and avoid amputations. About 85,000 Americans lose limbs each year to these issues. A topical gel that works locally avoids whole-body side effects from pills or IV drugs. Success here opens doors for other infections too.Â
For investors, micro-cap biotechs carry high risk but big rewards. Lakewood-Amedex timed its Nasdaq debut well before this data drop. Positive milestones like this de-risk the path to approval. The diabetic ulcer space grows at 6% yearly. Players range from big pharma to small innovators. Nu-3 stands out for its resistance profile. Watch for trial updates as Phase 2b ramps up.
AMR threatens global health more than some viruses. Everyday antibiotics fail faster now. Labs breed superbugs on purpose to test new drugs. Nu-3 passed with flying colors. This suggests real-world staying power. Other firms chase similar goals, but Bisphosphocins target a weak spot in bacteria few drugs hit. Early trials confirm fast kill times, key for chronic wounds.
Lakewood-Amedex builds on years of research. From Phase 1 to now, data piles up steadily. The firm raised eyes with its direct listing, skipping traditional IPO hype. As diabetes spreads, demand for better ulcer treatments surges. Nu-3 could fill a gap where options fall short.
Strong lab data sets the stage for human proof. Phase 2b will test doses in real patients. Success means partnership talks or buyout buzz. For now, this release spotlights a biotech doing solid work in a vital area. Patients wait for options that heal without resistance worries.
